Tempus AI (TEM) shares gained 17.9% over the past month, outperforming peers like Claritev and iRhythm, driven by strong demand for healthcare AI. The company reported 28% revenue growth in its Data and Applications segment to $93.2M in Q2, with Insights revenues up 36%. However, TEM trades at a premium valuation of 6.59X sales versus the industry average of 4.70X, and its growth depends heavily on regulatory approvals and reimbursement decisions. Analysts recommend current holders maintain positions while prospective investors wait for a more favorable entry point.

Edelson Lechtzin LLP is investigating a data breach at the Shipping Association of New York and New Jersey after unauthorized access on May 27, 2026 exposed personal information of benefit plan participants. The Qilin ransomware group claimed responsibility for the theft. Affected data may include names, Social Security numbers, driver's license numbers, and medical information. The law firm is offering free case evaluations for potential class action claims.

iRhythm Holdings, a San Francisco-based heart-monitoring company, suffered a data breach in June 2026 affecting approximately 8 million patients. Unauthorized access to third-party business applications exposed sensitive patient information including names, contact details, insurance numbers, and device serial numbers. The company disclosed the incident to the SEC and began notifying affected individuals in October 2026. A national class action law firm is investigating potential claims for compensation.

iRhythm Holdings disclosed a cybersecurity incident involving unauthorized access to sensitive data on third-party-hosted business applications. A threat actor claimed possession of proprietary company data and patient health information, demanding payment to prevent public disclosure. The company confirmed data exfiltration but stated core operations, clinical systems, and patient safety remain unaffected. iRhythm maintains cybersecurity insurance and does not believe the incident will materially impact financial results.

iRhythm Technologies reported strong preliminary Q4 2025 results with full-year revenue exceeding guidance and 2026 guidance of $870-880M (17-18% YoY growth). However, the stock fell ~20% due to the delay of Zio MCT launch to 2027 and 2026 guidance missing Street expectations. William Blair analyst Brandon Vazquez believes the selloff is overblown and maintains an Outperform rating, adding the stock to their Conviction List at 7x 2026 sales valuation.

NEXGEL reported stable Q3 2025 revenue of $2.9 million, improved gross profit margins, and narrowed adjusted EBITDA losses. The company signed new partnerships, launched product lines, and received non-dilutive financing from Stada, positioning for potential growth in Q4.

The global cardiac monitoring devices market is projected to grow from USD 21 billion in 2024 to USD 32 billion by 2032, driven by rising cardiovascular disease prevalence, technological advancements in remote monitoring, and increasing health awareness.

A clinical trial showed home-based long-term continuous ECG monitoring using Zio device increased atrial fibrillation detection and reduced time to diagnosis in patients aged 65+ with moderate to high stroke risk.

A shareholder filed a class action lawsuit against iRhythm Technologies, Inc. (IRTC), a digital healthcare company, alleging that the company misled investors about its Zio AT monitor. The court denied the defendants' motion to dismiss, allowing the litigation to proceed.

The AI in remote patient monitoring market is witnessing strong growth, driven by the increasing prevalence of chronic illnesses and a rise in product innovation, global investments in digital health infrastructure, and a focus on proactive, data-centric healthcare approaches.

iRhythm Technologies reported strong Q1 2025 results, with revenue growing 20.3% year-over-year driven by increased demand for its Zio services. The company's gross margin also improved, and it provided an upbeat guidance for fiscal 2025. Analysts have turned bullish on the stock, with Wells Fargo upgrading it to Overweight.

Kaskela Law LLC is investigating iRhythm Technologies, Inc. (IRTC) on behalf of long-term shareholders. A securities fraud complaint was filed against iRhythm, alleging the company made false and misleading statements about its Zio AT heart monitoring device.